Mikhail Alekseevich Osadchuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mikhail Alekseevich Osadchuk has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey M. Osadchuk
Russian Medical Academy of Continuous Professional Education
12 shared publications - Ekaterina D. Mironova
Sechenov First Moscow State Medical University (Sechenov University)
9 shared publications M A Osadchuk
Sechenov First Moscow State Medical University (Sechenov University)
9 shared publicationsI M Kvetnoĭ
8 shared publications- Irina D. Loranskaya
Russian Medical Academy of Continuous Professional Education
8 shared publications - Elena Vitalyevna Sayutina
I.M. Sechenov First Moscow State Medical University
7 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2026 (4) , 32-37
Specific features of arterial hypertension in various metabolic phenotypes of obesity
The adipose tissue, selectively affecting the metabolic profile, forms various phenotypes of metabolic health. The excess visceral fat can form both favorable metabolic phenotypes and unfavorable ones – associated pathogenically with arterial hypertension. This study is aimed at determination of the specific features of arterial hypertension in various metabolic phenotypes of obesity.
- 6 August 2026
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2026 (4) , 32-37
Open AccessSpecific features of arterial hypertension in various metabolic phenotypes of obesity
The adipose tissue, selectively affecting the metabolic profile, forms various phenotypes of metabolic health. The excess visceral fat can form both favorable metabolic phenotypes and unfavorable ones – associated pathogenically with arterial hypertension. This study is aimed at determination of the specific features of arterial hypertension in various metabolic phenotypes of obesity.
- Open Access
- 30 June 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (3) , 34-40
Treatment of Irritable Bowel Syndrome in Patients with Elevated Levels of Anxiety and/or Depression: Results of the Prospective Non-interventional Observational Program «KOMETA»
Aim: to evaluate the efficacy and safety of Kolofort ® in patients with irritable bowel syndrome accompanied by an anxiety-depressive disorder. Materials and methods. A total of 70 patients with irritable bowel syndrome confirmed by Rome IV criteria and a HADS (Hospital Anxiety and Depression Scale) score of ≥ 8 points were included in an open, prospective, observational, non-interventional program. Patients received Kolofort ® at a dose of 2 tablets twice daily for 8 weeks. The efficacy of the therapy was assessed according to the HADS, the Visual Analogue Scale for pain (VAS), and the Epworth Sleepiness Scale. Results. After 8 weeks of therapy, the severity of anxiety and depression was significantly reduced ( p < 0.0001): the mean score on the anxiety subscale decreased from 11.1 ± 2.4 to 5.3 ± 3.0, and from 7.6 ± 3.3 to 3.5 ± 2.8 on the depression subscale. The intensity of abdominal pain according to the VAS decreased from 4.8 ± 1.8 to 1.0 ± 1.0 ( p < 0.0001). Clinically significant pain reduction (≥30 % from baseline) was recorded in 92.9 % of patients. The level of daytime sleepiness according to the Epworth scale decreased from 6.7 ± 4.2 to 4.0 ± 2.2 ( p < 0.0001). Analysis of variance showed an association between reduced anxiety and decreased abdominal pain ( p = 0.0058). Conclusion. The results of the observational program demonstrate the efficacy and safety of Kolofort ® in the treatment of irritable bowel syndrome accompanied by elevated anxiety and/or depression. The synergistic effect of the drug components provides improvement in both somatic and psycho-emotional symptoms of irritable bowel syndrome.
- 30 June 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (3) , 34-40
Open AccessTreatment of Irritable Bowel Syndrome in Patients with Elevated Levels of Anxiety and/or Depression: Results of the Prospective Non-interventional Observational Program «KOMETA»
Aim: to evaluate the efficacy and safety of Kolofort ® in patients with irritable bowel syndrome accompanied by an anxiety-depressive disorder. Materials and methods. A total of 70 patients with irritable bowel syndrome confirmed by Rome IV criteria and a HADS (Hospital Anxiety and Depression Scale) score of ≥ 8 points were included in an open, prospective, observational, non-interventional program. Patients received Kolofort ® at a dose of 2 tablets twice daily for 8 weeks. The efficacy of the therapy was assessed according to the HADS, the Visual Analogue Scale for pain (VAS), and the Epworth Sleepiness Scale. Results. After 8 weeks of therapy, the severity of anxiety and depression was significantly reduced ( p < 0.0001): the mean score on the anxiety subscale decreased from 11.1 ± 2.4 to 5.3 ± 3.0, and from 7.6 ± 3.3 to 3.5 ± 2.8 on the depression subscale. The intensity of abdominal pain according to the VAS decreased from 4.8 ± 1.8 to 1.0 ± 1.0 ( p < 0.0001). Clinically significant pain reduction (≥30 % from baseline) was recorded in 92.9 % of patients. The level of daytime sleepiness according to the Epworth scale decreased from 6.7 ± 4.2 to 4.0 ± 2.2 ( p < 0.0001). Analysis of variance showed an association between reduced anxiety and decreased abdominal pain ( p = 0.0058). Conclusion. The results of the observational program demonstrate the efficacy and safety of Kolofort ® in the treatment of irritable bowel syndrome accompanied by elevated anxiety and/or depression. The synergistic effect of the drug components provides improvement in both somatic and psycho-emotional symptoms of irritable bowel syndrome.
- 29 June 2026
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2026 (2) , 52-58
Clinical efficiency of rivaroxaban for prevention of thromboembolic complications in patients with high cardio-metabolic risk
Thromboembolic complications in individuals with high cardiometabolic risk are among the leading causes of cardiovascular mortality in the world. Rivaroxaban is an oral inhibitor of factor X (Stuart-Prower factor) approved for prevention of thromboembolic complications in many countries. The article evaluates clinical efficiency of rivaroxaban in reducing the possibility of development of thromboembolic complications in patients with high cardiometabolic risk with non-valvular atrial fibrillation coupled with obesity, arterial hypertension and hyperlipidemia.
- 29 June 2026
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2026 (2) , 52-58
Clinical efficiency of rivaroxaban for prevention of thromboembolic complications in patients with high cardio-metabolic risk
Thromboembolic complications in individuals with high cardiometabolic risk are among the leading causes of cardiovascular mortality in the world. Rivaroxaban is an oral inhibitor of factor X (Stuart-Prower factor) approved for prevention of thromboembolic complications in many countries. The article evaluates clinical efficiency of rivaroxaban in reducing the possibility of development of thromboembolic complications in patients with high cardiometabolic risk with non-valvular atrial fibrillation coupled with obesity, arterial hypertension and hyperlipidemia.
- Open Access
- 21 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4634
Plant-Derived Bioactive Metabolites from the Sonoran Desert: Redox Regulation, Nrf2/NF-κB Signaling, and Emerging Therapeutic Applications
Plant-derived bioactive metabolites have emerged as promising modulators of oxidative stress and inflammation, two interconnected processes involved in the pathogenesis of numerous chronic diseases. Arid ecosystems, particularly the Sonoran Desert, constitute an underexplored source of structurally diverse phytochemicals with significant pharmacological potential. This review provides a comprehensive overview of major classes of plant-derived bioactives, including polyphenols, flavonoids, terpenoids, and alkaloids, with emphasis on their molecular mechanisms of antioxidant and anti-inflammatory action. These compounds exert cytoprotective effects through direct reactive oxygen species (ROS) scavenging and indirect regulation of endogenous defense systems, primarily via activation of the Nrf2/Keap1 pathway and suppression of NF-κB signaling. Additional pathways, including MAPK, PI3K/Akt, AMPK, and mitochondrial regulatory networks, are discussed as critical mediators of redox balance and inflammatory control. Particular attention is given to Sonoran Desert plant species such as Bucida buceras, Phoradendron californicum, Larrea tridentata, Opuntia spp., and Agave deserti, all of which demonstrate promising biological activities associated with enhanced adaptation to environmental stress. Experimental approaches used to evaluate phytochemical bioactivity, including chemical assays, cellular models, omics technologies, and translational strategies, are also examined. Furthermore, this review discusses current limitations related to bioavailability, phytochemical variability, and clinical validation, highlighting emerging nanodelivery systems and precision medicine approaches as potential solutions. Collectively, the evidence supports the therapeutic relevance of Sonoran Desert plant bioactives as multi-target agents for modulating oxidative stress, inflammation, and chronic disease progression.
- 21 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4634
Open AccessPlant-Derived Bioactive Metabolites from the Sonoran Desert: Redox Regulation, Nrf2/NF-κB Signaling, and Emerging Therapeutic Applications
Plant-derived bioactive metabolites have emerged as promising modulators of oxidative stress and inflammation, two interconnected processes involved in the pathogenesis of numerous chronic diseases. Arid ecosystems, particularly the Sonoran Desert, constitute an underexplored source of structurally diverse phytochemicals with significant pharmacological potential. This review provides a comprehensive overview of major classes of plant-derived bioactives, including polyphenols, flavonoids, terpenoids, and alkaloids, with emphasis on their molecular mechanisms of antioxidant and anti-inflammatory action. These compounds exert cytoprotective effects through direct reactive oxygen species (ROS) scavenging and indirect regulation of endogenous defense systems, primarily via activation of the Nrf2/Keap1 pathway and suppression of NF-κB signaling. Additional pathways, including MAPK, PI3K/Akt, AMPK, and mitochondrial regulatory networks, are discussed as critical mediators of redox balance and inflammatory control. Particular attention is given to Sonoran Desert plant species such as Bucida buceras, Phoradendron californicum, Larrea tridentata, Opuntia spp., and Agave deserti, all of which demonstrate promising biological activities associated with enhanced adaptation to environmental stress. Experimental approaches used to evaluate phytochemical bioactivity, including chemical assays, cellular models, omics technologies, and translational strategies, are also examined. Furthermore, this review discusses current limitations related to bioavailability, phytochemical variability, and clinical validation, highlighting emerging nanodelivery systems and precision medicine approaches as potential solutions. Collectively, the evidence supports the therapeutic relevance of Sonoran Desert plant bioactives as multi-target agents for modulating oxidative stress, inflammation, and chronic disease progression.
- Open Access
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 110-114
Chronic gastroduodenitis, associated and not associated with Helicobacter pylori infection, and its relationship with functional intestinal pathology depending on the content of fecal calprotectin
Background. In recent years, the role of chronic gastroduodenitis in the occurrence of functional intestinal diseases within the framework of the crossover syndrome, which occurs against the background of minimal inflammation in the stomach and intestines associated with Helicobacter pylori infection, has become increasingly relevant. Aim. To determine the relationship of chronic gastroduodenitis, associated and not associated with H. pylori infection, with the level of fecal calprotectin (FC) and clinical symptoms of functional intestinal disorders. Materials and methods. The study included 158 patients with chronic gastroduodenitis: group 1 (80 patients with gastroduodenitis associated with H. pylori infection in the stomach) and group 2 (76 patients without H. pylori infection). All patients had clinical symptoms of the gastrointestinal tract for at least a year. The patients underwent esophagoduodenoscopy and colonoscopy. Verification of H. pylori was based on data from histiobacterioscopy of impression smears from the mucous membrane of the antrum of the stomach. FC content was determined using an express analyzer. Results. Patients of the first group significantly more often complained of pain, a burning sensation and fullness after eating in the epigastric region, nausea, belching, heartburn, flatulence, pain along the large intestine, a feeling of incomplete evacuation after defecation compared to the group without H. pylori infection. At the same time, in patients with H. pylori infection, FC values were most often determined in the range from 50 to 200 μg/g – in 28.75%, and in patients not infected with H. pylori infection – 13.15% (p 0.05). Conclusion. The studies conducted indicate the presence of a statistically significant relationship between chronic gastroduodenitis and functional intestinal disorders, which can be bidirectional in nature, the basis of which is minimal inflammation caused by the presence of H. pylori infection and increased production of FC.
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 110-114
Open AccessChronic gastroduodenitis, associated and not associated with Helicobacter pylori infection, and its relationship with functional intestinal pathology depending on the content of fecal calprotectin
Background. In recent years, the role of chronic gastroduodenitis in the occurrence of functional intestinal diseases within the framework of the crossover syndrome, which occurs against the background of minimal inflammation in the stomach and intestines associated with Helicobacter pylori infection, has become increasingly relevant. Aim. To determine the relationship of chronic gastroduodenitis, associated and not associated with H. pylori infection, with the level of fecal calprotectin (FC) and clinical symptoms of functional intestinal disorders. Materials and methods. The study included 158 patients with chronic gastroduodenitis: group 1 (80 patients with gastroduodenitis associated with H. pylori infection in the stomach) and group 2 (76 patients without H. pylori infection). All patients had clinical symptoms of the gastrointestinal tract for at least a year. The patients underwent esophagoduodenoscopy and colonoscopy. Verification of H. pylori was based on data from histiobacterioscopy of impression smears from the mucous membrane of the antrum of the stomach. FC content was determined using an express analyzer. Results. Patients of the first group significantly more often complained of pain, a burning sensation and fullness after eating in the epigastric region, nausea, belching, heartburn, flatulence, pain along the large intestine, a feeling of incomplete evacuation after defecation compared to the group without H. pylori infection. At the same time, in patients with H. pylori infection, FC values were most often determined in the range from 50 to 200 μg/g – in 28.75%, and in patients not infected with H. pylori infection – 13.15% (p 0.05). Conclusion. The studies conducted indicate the presence of a statistically significant relationship between chronic gastroduodenitis and functional intestinal disorders, which can be bidirectional in nature, the basis of which is minimal inflammation caused by the presence of H. pylori infection and increased production of FC.
- 20 February 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (1)
The effect of metabolic syndrome on the frequency and outcome of malignant neoplasms
Objective. To assess the likelihood of developing malignant neoplasms, the features of their course and the five-year outcome, depending on the dynamics of anthropometric and biochemical parameters in patients with metabolic syndrome (MS). Material and methods. In a retrospective cohort study, data from 1993 patients were analyzed, of which 994 patients with MS formed the main group, 999 patients without MS — the comparison group. MS was determined by the presence of abdominal obesity (AO) in combination with two or more additional signs (dyslipidemia, hyperglycemia, arterial hypertension). The course and outcome of the disease in cancer patients with MS were considered depending on the dynamics of MS indicators one year and five years after the diagnosis was confirmed. Statistical analysis was performed using the SPSS INC 27.0 program. Results. In patients with MS, cases of malignant neoplasms were noted in 18.6% of patients, while in the absence of MS — only 7.3%. In an intergroup comparison, these differences reached the criteria of statistical significance (p<0.05). Normalization of biochemical parameters such as HDL, TG, and glucose levels one year and five years after cancer diagnosis reduces the risk of metastasis and recurrence and reduces the risk of death (p<0.05). On the contrary, an increase in the deviation from the norm leads to a progression of the process and increases the frequency of deaths. Conclusion. MS and its components are risk factors for cancer of any localization. With the normalization of previously identified changes that meet additional criteria for MS, a year after the identified oncopathology, the risk of metastasis and recurrence of the process decreases, and after five years, the risk of mortality from cancer decreases.
- 20 February 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (1)
The effect of metabolic syndrome on the frequency and outcome of malignant neoplasms
Objective. To assess the likelihood of developing malignant neoplasms, the features of their course and the five-year outcome, depending on the dynamics of anthropometric and biochemical parameters in patients with metabolic syndrome (MS). Material and methods. In a retrospective cohort study, data from 1993 patients were analyzed, of which 994 patients with MS formed the main group, 999 patients without MS — the comparison group. MS was determined by the presence of abdominal obesity (AO) in combination with two or more additional signs (dyslipidemia, hyperglycemia, arterial hypertension). The course and outcome of the disease in cancer patients with MS were considered depending on the dynamics of MS indicators one year and five years after the diagnosis was confirmed. Statistical analysis was performed using the SPSS INC 27.0 program. Results. In patients with MS, cases of malignant neoplasms were noted in 18.6% of patients, while in the absence of MS — only 7.3%. In an intergroup comparison, these differences reached the criteria of statistical significance (p<0.05). Normalization of biochemical parameters such as HDL, TG, and glucose levels one year and five years after cancer diagnosis reduces the risk of metastasis and recurrence and reduces the risk of death (p<0.05). On the contrary, an increase in the deviation from the norm leads to a progression of the process and increases the frequency of deaths. Conclusion. MS and its components are risk factors for cancer of any localization. With the normalization of previously identified changes that meet additional criteria for MS, a year after the identified oncopathology, the risk of metastasis and recurrence of the process decreases, and after five years, the risk of mortality from cancer decreases.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (4) , 86-93
Strategy for early diagnosis and prevention of pancreatic cancer
Pancreatic cancer (PC) is one of the most common and prognostically unfavorable malignancies of the digestive system. In recent years, its incidence has been steadily increasing, underscoring the need to improve strategies for early detection. Timely diagnosis plays a pivotal role, as it enables optimal therapeutic decision-making and improves survival outcomes. Objective. To summarize current perspectives on the early diagnosis and prevention of pancreatic cancer. Key points. Early detection is essential primarily in high-risk populations, including individuals with genetic predisposition and those with a personal history of pancreatic neoplasia. In these high-risk groups, screening programs should incorporate regularly scheduled imaging—primarily magnetic resonance imaging — with or without the use of biomarkers such as CA 19-9. Currently, there is insufficient evidence to support population-wide screening due to the lack of cost-effective tests. Preventive strategies include lifestyle and wellness interventions, general cancer screening, mental health improvement, and the targeted use of digital biomarkers. Chemoprevention approaches for high-risk individuals are discussed, with evidence suggesting a reduced likelihood of PC development in diabetic patients receiving metformin or aspirin. Conclusion. Despite recent progress, the majority of pancreatic cancer cases continue to be diagnosed at advanced stages. Early detection and prompt treatment remain the most effective means of improving outcomes. A comprehensive diagnostic approach that integrates laboratory, imaging, and histopathological data with artificial intelligence-based tools holds promise for facilitating earlier disease identification.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (4) , 86-93
Strategy for early diagnosis and prevention of pancreatic cancer
Pancreatic cancer (PC) is one of the most common and prognostically unfavorable malignancies of the digestive system. In recent years, its incidence has been steadily increasing, underscoring the need to improve strategies for early detection. Timely diagnosis plays a pivotal role, as it enables optimal therapeutic decision-making and improves survival outcomes. Objective. To summarize current perspectives on the early diagnosis and prevention of pancreatic cancer. Key points. Early detection is essential primarily in high-risk populations, including individuals with genetic predisposition and those with a personal history of pancreatic neoplasia. In these high-risk groups, screening programs should incorporate regularly scheduled imaging—primarily magnetic resonance imaging — with or without the use of biomarkers such as CA 19-9. Currently, there is insufficient evidence to support population-wide screening due to the lack of cost-effective tests. Preventive strategies include lifestyle and wellness interventions, general cancer screening, mental health improvement, and the targeted use of digital biomarkers. Chemoprevention approaches for high-risk individuals are discussed, with evidence suggesting a reduced likelihood of PC development in diabetic patients receiving metformin or aspirin. Conclusion. Despite recent progress, the majority of pancreatic cancer cases continue to be diagnosed at advanced stages. Early detection and prompt treatment remain the most effective means of improving outcomes. A comprehensive diagnostic approach that integrates laboratory, imaging, and histopathological data with artificial intelligence-based tools holds promise for facilitating earlier disease identification.
- Open Access
- 9 December 2025
- Published by MDPI AG in Preprints.org
Molecular Crosstalk of the Motilin–Somatostatin–VEGF Axis in Duodenal Dysfunction Underlying IBS-C and Functional Dyspepsia
The duodenal mucosa plays a pivotal role in gastrointestinal physiology through its endocrine cells (ECs), which secrete key regulatory factors including motilin (MLN), somatostatin (SS), and vascular endothelial growth factor (VEGF). Alterations in the expression of these mediators have been implicated in the pathogenesis of irritable bowel syndrome with constipation (IBS-C) and its overlap with functional dyspepsia (FD). In this study, immunohistochemical and morphometric analyses were performed on duodenal retrobulbar part biopsies obtained from patients with IBS-C, IBS-C combined with FD, and healthy controls. The results demonstrated a significant reduction in MLN-secreting ECs, accompanied by increased SS- and VEGF-positive ECs in IBS-C with FD patients compared to other groups. These endocrine alterations were associated with more severe abdominal pain, higher body mass index, and greater anxiety and depression scores. The findings highlight the contribution of duodenal EC dysfunction to impaired motility, visceral hypersensitivity, and low-grade inflammation, supporting the concept of the duodenum as a critical neuroendocrine hub within the gut–brain axis. This study underscores the relevance of MLN, SS, and VEGF as potential biomarkers and therapeutic targets in IBS-C and FD comorbidity.
- 9 December 2025
- Published by MDPI AG in Preprints.org
Open AccessMolecular Crosstalk of the Motilin–Somatostatin–VEGF Axis in Duodenal Dysfunction Underlying IBS-C and Functional Dyspepsia
The duodenal mucosa plays a pivotal role in gastrointestinal physiology through its endocrine cells (ECs), which secrete key regulatory factors including motilin (MLN), somatostatin (SS), and vascular endothelial growth factor (VEGF). Alterations in the expression of these mediators have been implicated in the pathogenesis of irritable bowel syndrome with constipation (IBS-C) and its overlap with functional dyspepsia (FD). In this study, immunohistochemical and morphometric analyses were performed on duodenal retrobulbar part biopsies obtained from patients with IBS-C, IBS-C combined with FD, and healthy controls. The results demonstrated a significant reduction in MLN-secreting ECs, accompanied by increased SS- and VEGF-positive ECs in IBS-C with FD patients compared to other groups. These endocrine alterations were associated with more severe abdominal pain, higher body mass index, and greater anxiety and depression scores. The findings highlight the contribution of duodenal EC dysfunction to impaired motility, visceral hypersensitivity, and low-grade inflammation, supporting the concept of the duodenum as a critical neuroendocrine hub within the gut–brain axis. This study underscores the relevance of MLN, SS, and VEGF as potential biomarkers and therapeutic targets in IBS-C and FD comorbidity.
- 31 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (10) , 115-122
Thrombotic complications in pancreatitis: diagnostics and prevention
Acute (AP) and chronic pancreatitis (CP) — one of the most important healthcare issues, the solution of which is associated with significant material costs due to the high incidence of this pathology, difficulties in diagnosis and treatment, often complicated course of the disease. In this connection, special attention should be paid to the thrombotic complication of pancreatitis, namely splanchnic venous thrombosis (SVT), development of which significantly increases the probability of adverse outcome. Currently, there are no specific recommendations for the treatment of SVT, and some issues of anticoagulant therapy are still controversial. Objective. To perform optimization of the treatment algorithm for patients with pancreatitis complicated by splanchnic venous thrombosis. Materials and methods. A systematic search in four databases, namely MedLine (through PubMed), Embase, Cochrane (CENTRAL) and Scopus was performed based on the study of scientific sources for the period from 2010 to 2025 using the following keywords: «acute pancreatitis», «chronic pancreatitis», «thrombosis of splanchnic veins», «acute thrombosis», «chronic thrombosis», «recanalization», «anticoagulant therapy». Results. The need for anticoagulant therapy in patients with AP and CP, both in acute and chronic thrombosis, has been shown during the study. In acute thrombosis, therapy should start with application of low-molecular-weight heparins, and when the international normalized ratio of 2—3 is reached, transfer to therapy with oral anticoagulants or vitamin K antagonists and treatment up to 6 months are indicated. Long-term treatment with anticoagulants is required in chronic thrombosis with persistent risk factors, and in the presence of transient risk factors long-term treatment with anticoagulants is indicated in recurrent thrombosis and episodes of intestinal ischemia. Conclusion. Presently, there are many controversial issues on the management of patients with pancreatitis complicated by splanchnic venous thrombosis, that is associated with the risk of increased bleeding frequency. The optimal algorithm for treatment of patients with this pathology has been determined based on the study of modern sources.
- 31 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (10) , 115-122
Thrombotic complications in pancreatitis: diagnostics and prevention
Acute (AP) and chronic pancreatitis (CP) — one of the most important healthcare issues, the solution of which is associated with significant material costs due to the high incidence of this pathology, difficulties in diagnosis and treatment, often complicated course of the disease. In this connection, special attention should be paid to the thrombotic complication of pancreatitis, namely splanchnic venous thrombosis (SVT), development of which significantly increases the probability of adverse outcome. Currently, there are no specific recommendations for the treatment of SVT, and some issues of anticoagulant therapy are still controversial. Objective. To perform optimization of the treatment algorithm for patients with pancreatitis complicated by splanchnic venous thrombosis. Materials and methods. A systematic search in four databases, namely MedLine (through PubMed), Embase, Cochrane (CENTRAL) and Scopus was performed based on the study of scientific sources for the period from 2010 to 2025 using the following keywords: «acute pancreatitis», «chronic pancreatitis», «thrombosis of splanchnic veins», «acute thrombosis», «chronic thrombosis», «recanalization», «anticoagulant therapy». Results. The need for anticoagulant therapy in patients with AP and CP, both in acute and chronic thrombosis, has been shown during the study. In acute thrombosis, therapy should start with application of low-molecular-weight heparins, and when the international normalized ratio of 2—3 is reached, transfer to therapy with oral anticoagulants or vitamin K antagonists and treatment up to 6 months are indicated. Long-term treatment with anticoagulants is required in chronic thrombosis with persistent risk factors, and in the presence of transient risk factors long-term treatment with anticoagulants is indicated in recurrent thrombosis and episodes of intestinal ischemia. Conclusion. Presently, there are many controversial issues on the management of patients with pancreatitis complicated by splanchnic venous thrombosis, that is associated with the risk of increased bleeding frequency. The optimal algorithm for treatment of patients with this pathology has been determined based on the study of modern sources.
- Open Access
- 26 September 2025
- Published by MDPI AG in Preprints.org
Advances in the Molecular Pathophysiology and Emerging Therapeutic Strategies for Diabetic Retinopathy
Diabetic retinopathy (DR) is a major microvascular complication of diabetes and a leading cause of vision loss in working-age adults worldwide. The pathophysiology of DR is complex and involves oxidative stress, inflammation, retinal pigment epithelium (RPE) dysfunction, and abnormal angiogenesis. Recent insights into the molecular mechanisms underlying DR have opened new avenues for targeted and personalized therapeutic strategies. In this review, we examine the advances in the understanding of oxidative damage, RPE impairment, and proangiogenic signaling in DR progression. We also highlight emerging treatment modalities, including anti-VEGF agents, gene therapy, and nutraceutical interventions. Future directions emphasize the integration of omics technologies and precision medicine approaches for individualized management. This work provides a critical synthesis of recent findings and identifies promising avenues for research and clinical intervention in DR.
- 26 September 2025
- Published by MDPI AG in Preprints.org
Open AccessAdvances in the Molecular Pathophysiology and Emerging Therapeutic Strategies for Diabetic Retinopathy
Diabetic retinopathy (DR) is a major microvascular complication of diabetes and a leading cause of vision loss in working-age adults worldwide. The pathophysiology of DR is complex and involves oxidative stress, inflammation, retinal pigment epithelium (RPE) dysfunction, and abnormal angiogenesis. Recent insights into the molecular mechanisms underlying DR have opened new avenues for targeted and personalized therapeutic strategies. In this review, we examine the advances in the understanding of oxidative damage, RPE impairment, and proangiogenic signaling in DR progression. We also highlight emerging treatment modalities, including anti-VEGF agents, gene therapy, and nutraceutical interventions. Future directions emphasize the integration of omics technologies and precision medicine approaches for individualized management. This work provides a critical synthesis of recent findings and identifies promising avenues for research and clinical intervention in DR.